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Interleukin-17-expressing CD4+ T helper 17 (Th17) cells are considered as critical regulators of multiple sclerosis disease activity.
However, depending on the species and pro-inﬂammatory milieu, Th17 cells are functionally heterogeneous, consisting of sub-
populations that differentially produce interleukin-17, interferon-gamma and granulocyte macrophage colony-stimulating factor. In
the current study, we studied distinct effector phenotypes of human Th17 cells and their correlation with disease activity in
multiple sclerosis patients. T helper memory populations single- and double-positive for C-C chemokine receptor 6 (CCR6) and
CXC chemokine receptor 3 (CXCR3) were functionally assessed in blood and/or cerebrospinal ﬂuid from a total of 59 patients
with clinically isolated syndrome, 35 untreated patients and 24 natalizumab-treated patients with relapsing-remitting multiple
sclerosis, and nine patients with end-stage multiple sclerosis. Within the clinically isolated syndrome group, 23 patients had a
second attack within 1 year and 26 patients did not experience subsequent attacks during a follow-up of 45 years. Low
frequencies of T helper 1 (Th1)-like Th17 (CCR6+CXCR3+), and not Th17 (CCR6+CXCR3) effector memory populations
in blood strongly associated with a rapid diagnosis of clinically deﬁnite multiple sclerosis. In cerebrospinal ﬂuid of clinically
isolated syndrome and relapsing-remitting multiple sclerosis patients, Th1-like Th17 effector memory cells were abundant and
showed increased production of interferon-gamma and granulocyte macrophage colony-stimulating factor compared to paired
CCR6+ and CCR6CD8+ T cell populations and their blood equivalents after short-term culturing. Their local enrichment was
conﬁrmed ex vivo using cerebrospinal ﬂuid and brain single-cell suspensions. Across all pro-inﬂammatory T helper cells analysed in
relapsing-remitting multiple sclerosis blood, Th1-like Th17 subpopulation T helper 17.1 (Th17.1; CCR6+CXCR3+CCR4) ex-
pressed the highest very late antigen-4 levels and selectively accumulated in natalizumab-treated patients who remained free of
clinical relapses. This was not found in patients who experienced relapses during natalizumab treatment. The enhanced potential of
Th17.1 cells to inﬁltrate the central nervous system was supported by their predominance in cerebrospinal ﬂuid of early multiple
sclerosis patients and their preferential transmigration across human brain endothelial layers. These ﬁndings reveal a dominant
contribution of Th1-like Th17 subpopulations, in particular Th17.1 cells, to clinical disease activity and provide a strong rationale
for more speciﬁc and earlier use of T cell-targeted therapy in multiple sclerosis.
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Introduction
Multiple sclerosis is mediated by effector T cells trafﬁcking
from the periphery into the CNS to trigger local inﬂamma-
tion, demyelination and neurodegeneration (Dendrou et al.,
2015). Although current T cell-directed treatment attenu-
ates disease activity, it often causes serious complications
and does not prevent disease progression in multiple scler-
osis (Ransohoff et al., 2015). To improve treatment efﬁcacy
and risk management, more in-depth insight into human
effector T cells during multiple sclerosis onset is warranted.
In the earliest clinical presentation of multiple sclerosis,
clinically isolated syndrome (CIS), increased peripheral
CD4+ T cell activation is linked to the occurrence of a
second attack (Corvol et al., 2008). However, substantial
knowledge has been gained about speciﬁc human T helper
(Th) functions, and the exact nature of the pro-inﬂamma-
tory T helper subsets involved in multiple sclerosis is in-
completely understood.
Both Th1 and Th17 cells are known to be encephalito-
genic, but use distinct transmigration routes to enter the
CNS. In experimental autoimmune encephalomyelitis, Th1
cells preferentially migrate into the spinal cord, while Th17
cells mainly inﬁltrate the brain (Stromnes et al., 2008). This
is facilitated by their differential expression of pro-inﬂam-
matory cytokines, chemokine receptors and integrins (Bauer
et al., 2009; Reboldi et al., 2009; Larochelle et al., 2011).
Interleukin-17 (IL-17) and C-C chemokine receptor 6
(CCR6) are key determinants for Th17 transmigration
across the blood–brain barrier (Kebir et al., 2007; Reboldi
et al., 2009). IL-17 is generally considered as the signature
cytokine produced by CCR6-positive Th17 cells. However,
this greatly underestimates Th17 effector function, since
subpopulations also (co-)produce interferon-gamma (IFN-
g) and granulocyte macrophage colony-stimulating factor
(GM-CSF). Next to IL-17, also IFN-g and GM-CSF are
strongly produced by myelin-speciﬁc CCR6-positive T
helper cells in multiple sclerosis (Cao et al., 2015). Th17
polyfunctionality is differently regulated between species, as
reﬂected by the antagonistic regulation of IL-17 and
GM-CSF expression in human compared to murine T
helper cells (El-Behi et al., 2011; Noster et al., 2014;
Paterka et al., 2016). Particularly GM-CSF produced by T
helper cells is implicated as a critical mediator of multiple
sclerosis onset (Codarri et al., 2011; Hartmann et al., 2014).
The surface expression of another chemokine receptor,
CXCR3, deﬁnes Th17 cells with Th1-like features
(Acosta-Rodriguez et al., 2007). CCR6 and CXCR3 ex-
pression on CD4+ T cells is controlled by transcription
factors RORgt and T-bet, respectively, which were origin-
ally associated with IL-17/IFN-g double-production
(Acosta-Rodriguez et al., 2007). However, recent ﬁndings
demonstrate more heterogeneous IL-17, IFN-g and GM-
CSF expression proﬁles in Th17 cells, depending on the
inﬂammatory milieu (Duhen and Campbell, 2014).
Besides CCR6 and CXCR3, also the presence of the
a4b1 integrin very late antigen-4 (VLA-4), which is abun-
dant on Th17 cells in multiple sclerosis CSF (Brucklacher-
Waldert et al., 2009), determines T cell transmigration
capacities. Anti-VLA-4 monoclonal antibody natalizumab
is currently one of the most effective therapies in multiple
sclerosis, but relapses are still encountered after 1 year in
about one-third of treated patients (Polman et al., 2006).
Understanding which distinct pro-inﬂammatory T helper
subsets are targeted by natalizumab will help to better pre-
dict treatment response in multiple sclerosis (Prosperini
et al., 2012).
Here, blood and CSF samples from CIS and both untreated
and natalizumab-treated relapsing-remitting multiple sclerosis
(RRMS) patients were assessed for distribution, memory
phenotype, activation and pro-inﬂammatory capacity of
Th17 subsets. We reveal that IFN-g-/GM-CSF-producing
(CCR6+CXCR3+), but not IL-17-producing (CCR6+
CXCR3) Th17 effector cells are key regulators of multiple
sclerosis onset. A Th1-like Th17 subpopulation termed
Th17.1 (CCR6+CXCR3+CCR4) is selectively targeted by
natalizumab in patients with multiple sclerosis who remained
free of clinical relapses. This work supports the design and
early use of therapeutic strategies against Th17.1 cells to pre-
vent relapses in multiple sclerosis.
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Materials and methods
Patients
Characteristics of patients and controls in the screening
cohorts are summarized in Table 1. Main experimental re-
sults were conﬁrmed using additional cohorts (Supplementary
Table 1). All CIS and RRMS patients as well as controls were
included at Erasmus MC (Rotterdam, The Netherlands), which
is a national tertiary referral centre for patients with multiple
sclerosis (MS Center ErasMS). All primary material was
collected between 2007 and 2017.
For blood analyses, we selected 23 patients with CIS who
did not experience a second clinical attack for at least 5 years
of follow-up (CIS-CIS) and 26 CIS patients who were diag-
nosed with clinically deﬁnite multiple sclerosis (CDMS) within
1 year after CIS (CIS-CDMS) from our prospective cohort.
None of these patients were treated with disease-modifying
therapies before or at time of sampling. CIS was deﬁned as
a ﬁrst clinical attack of demyelination in the CNS (Miller
et al., 2012). CDMS diagnosis was made when a patient
experienced two attacks with clinical evidence of two separate
lesions according to the Poser criteria (Poser et al., 1983). A
relapse was deﬁned as subacute worsening of existing symp-
toms, or new symptoms after at least 30 days of improvement
or stable disease (Schumacher et al., 1965). Fatigue scores
were acquired at the time of the ﬁrst attack using the
self-administered Krupp’s Fatigue Severity Scale, as shown pre-
viously (Runia et al., 2015). Anti-EBNA1 IgG levels were
determined in plasma using a well-validated chemiluminescent
assay and analyser (Liaison XL; both Diasorin) according to
the manufacturers’ instructions at our local referral centre for
virus diagnostics (Erasmus MC).
Patients with RRMS were diagnosed according to the
McDonald 2010 criteria (Polman et al., 2011). Blood T
helper cell analyses were performed for 31 treatment-naı¨ve
RRMS patients, as well as for 24 RRMS patients before the
start and after 6 and 12 months of natalizumab therapy. The
median time between the last clinical attack and ﬁrst adminis-
tration of natalizumab was 2.8 months [interquartile range
(IQR): 1.7–6.3]. Seventeen of these patients (70.8%) were trea-
ted with disease-modifying therapy before initiation of natali-
zumab (14 with IFN-b, one with both dimethylfumarate and
ﬁngolimod, one with glatiramer acetate and one with
mitoxantron).
CSF with and without paired blood samples was obtained
from 14 patients with early-stage multiple sclerosis (ErasMS)
and nine with late-stage multiple sclerosis (Netherlands Brain
Bank, Amsterdam). In the early-stage multiple sclerosis group,
10 patients were CIS at the time of lumbar puncture and four
patients were diagnosed with RRMS within 6 months before
sampling. The median time between sampling and the last
clinical attack was 2.8 months (IQR: 1.3–5.8). Additional
autopsied brain tissues were obtained from ﬁve patients with
late-stage multiple sclerosis and two non-demented control
Table 1 Characteristics of patients and controls in screening cohorts
Blood, ex vivo
Cohort HC CIS-CIS CIS-CDMS RRMS, no
treatmenta
RRMS, NAT
treatmenta
Patients, n 19 16 16 18 17b
Gender, female, n (%) 16 (84) 11 (69) 13 (81) 15 (83) 12 (71)
Age in years, median (IQR)c 45 (35–49) 36 (27–40) 33 (28–37) 46 (37–50) 38 (30–46)d
Follow-up time in years, median (IQR) NA 6.8 (6.2–7.3) 4.1 (3.1–5.7) NA NA
Disease duration in months, median (IQR)e NA 2.0 (1.3–3.1) 2.0 (1.2–3.0) 120 (48–193) 92 (48–160)d
59 lesions on T2-weighted images at baseline, n (%) NA 3 (19) 10 (63) NA NA
CSF/brain, ex vivo CSF, TCC
Cohortf Early MS Late MS Late NDC Early MS Late MS
Patients, n (paired blood) 4 (4) 5 (5) 2 (2) 10 (4) 7 (7)g
Gender, female n (%) 2 (50) 5 (100) 1 (50) 10 (100) 5 (71)
Age in years, median (IQR)c 32 (18–41) 62 (44–72) 78 (NA) 33 (23–38) 70 (60–82)
Follow-up time in years, median (IQR) 0.3 (0.3–0.5) NA NA 1.5 (0.6–5.5) NA
Disease duration in months, median (IQR)e 3.8 (2.7–5.2) NA NA 3.8 (1.0–22.4) NA
PMD in hours, median (IQR) NA 8.5 (8.4–9.2) 6.1 (NA) NA 8.6 (8.3–9.3)
pH CSF, median (IQR) NA 6.3 (6.3–6.7) 6.5 (NA) NA 6.5 (6.3–6.7)
aRRMS according to the McDonald (2010) criteria.
bFourteen patients were included for in-depth analysis of Th17 subpopulations in blood. For three patients, T helper subsets were only used for analysis of pro-inflammatory cytokine
expression.
cAt the time of sampling.
dAt the time of pretreatment sampling.
eTime from CIS diagnosis to sampling.
fSamples obtained from either CIS and RRMS patients (‘early’) or deceased patients with multiple sclerosis and non-demented control subjects (‘late’).
gThree patients were also used for ex vivo CSF/brain T cell analysis.
HC = healthy control; MS = multiple sclerosis; NA = not applicable or available; NAT = natalizumab; NDC = non-demented control; PMD = post-mortem delay; TCC = T cell
culture.
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subjects (Netherlands Brain Bank). All study protocols were
approved by the medical ethics committee of the Erasmus
MC (Rotterdam) and VUmc (Amsterdam, The Netherlands).
Written informed consent was obtained from all included pa-
tients and controls.
Mononuclear cell isolation from
blood, CSF and brain tissue
Blood from patients and matched controls was collected using
Vacutainer CPT tubes (BD Biosciences) containing sodium hep-
arin. Peripheral blood mononuclear cells were isolated accord-
ing to the manufacturer’s instructions. After centrifugation,
cells were taken up in RPMI1640 (Lonza) containing 40%
foetal calf serum and 20% dimethyl sulfoxide (Sigma-Aldrich)
and stored in liquid nitrogen until further use. Surplus CSF of
patients with early-stage multiple sclerosis was obtained
through lumbar puncture for diagnostic purposes. Blood and
CSF samples from patients with late-stage multiple sclerosis
were acquired post-mortem through heart puncture and ven-
tricle drainage, respectively. Collection tubes with CSF were
centrifuged for 10min at 500g. Paired blood and blood from
buffy coats was diluted in phosphate-buffered saline (PBS),
after which mononuclear cells were isolated by density gradient
centrifugation using Ficoll Paque Plus (GE Healthcare). CSF
and blood mononuclear cell fractions were resuspended in
RPMI 1640 containing 10% heat inactivated human AB
serum (Sanquin) and 1% Pen/Strep (Lonza) and left to rest at
37C until further use. Brain tissue samples were processed and
single-cell suspensions were obtained as described previously
(van Nierop et al., 2017).
Short-term CSF and blood T cell
cultures
Short-term culturing of CSF-derived T cells was required to
obtain sufﬁcient cell numbers for ﬂuorescence-activated cell
sorting (FACS) and intracellular cytokine staining of the T
helper subsets of interest. CSF and blood T cells were cultured
as previously described (van Nierop et al., 2016). In short,
mononuclear cell fractions were treated for 13 to 15 days
with g-irradiated feeder cells (10  106 peripheral blood
mononuclear cells and 106 EBV B cell lines HAL-02 and
RS-411), phytohaemagglutinin-L (1 ng/ml; Sigma-Aldrich), IL-
2 (25 U/ml; Erasmus MC) and IL-15 (12.5 ng/ml; Miltenyi
Biotec) in RPMI1640 containing L-glutamine (Lonza), 1%
Pen/Strep and 10% heat-inactivated human AB serum. IL-2
and IL-15 were added every 3 to 4 days. Post-mortem CSF
samples were restimulated using the same protocol.
Antibodies and flow cytometry
Multicolour ﬂow cytometric analysis was performed using the
following ﬂuorochrome-labelled monoclonal anti-human anti-
bodies: CD3 BV785 (SK7), CD8 FITC (SK1), CD45RA APC-
H7 (HI100), HLA-DR FITC and BB515 (G46-6), VLA-4
BV711 and APC (9F10), CD45RO PerCP-Cy5.5 (UCHL1),
CD25 BV605 and APC-R700 (2A3), CD226 BB515 (DX11),
MCAM PerCP-Cy5.5 (P1H12), PSGL-1 APC (KPL-1), GM-
CSF BV421 and PE-CF594 (BVD2-21C11) (all BD
Biosciences), CD4 BV510 (OKT4), CD38 BV711 and PerCP-
Cy5.5 (HIT2), CXCR3 BV421, PE-Cy7 and APC (G025H7),
CCR6 PE (G034E3), CCR7 PE-CF594 (150503), CCR4 PE-
Cy7 and PE-Dazzle (L291H4), CD161 BV605 (HP-3G10),
IFN-g BV421 and BV711 (4S.B3), and IL-17A APC (BL168)
(all BioLegend). Cells were stained for 30min at 4C, mea-
sured with an LSRII-Fortessa ﬂow cytometer and analysed
using FACSDiva 6.1.2 software (both BD Biosciences). Th1,
Th17 and Th1-like Th17 cells were deﬁned based on markers
CCR6 and CXCR3 with and without the use of CCR4. For
analyses without CCR4, total CD4+ T cells were subdivided
into CCR6CXCR3+ (Th1), CCR6+CXCR3 (Th17) and
CCR6+CXCR3+ (Th1-like Th17) subsets. In each T helper
subset, the proportion of effector memory (CCR7
CD45RA) and central memory (CCR7CD45RA+) cells
was analysed. CCR4 was used as a marker to discriminate
CCR6CXCR3+CCR4 (Th1), CCR6+CXCR3CCR4+
(Th17), CCR6+CXCR3+CCR4 (Th17.1) and CCR6+
CXCR3+CCR4+ [Th17 double-positive (DP)] subpopulations
(Paulissen et al., 2015).
Intracellular cytokine staining
Th1 (CCR6CXCR3+ ), Th17 (CCR6+CXCR3), Th1-like
Th17 (CCR6+CXCR3+), as well as CCR6 and CCR6+
CD8+ T cells were sorted from blood and CSF T cell
memory pools (CD3+CD25/int CD45RO+CD45RA) using
a BD FACSAriaTM III cell sorter. Prior to isolation of T
helper memory subsets from buffy coats, CD4+ cells were
puriﬁed from the mononuclear cell fraction using CD4
microbeads and the autoMACS Pro Separator (both Miltenyi
Biotec). Cells were stimulated with phorbol 12-myristate
13-acetate (PMA; 1:2000) and ionomycin (1:500; both
Sigma-Aldrich) for 5 h. GolgiStopTM (1:1500; BD
Biosciences) was added during the last 2.5 h of stimulation.
Stimulated cells were ﬁxed and permeabilized using the BD
Cytoﬁx/CytopermTM kit (BD Biosciences) according to the
provided protocol, and stained for IFN-g, GM-CSF and IL-
17A within the same tube.
RNA isolation and quantitative PCR
Sorted T cell subsets were washed with PBS and resuspended
in RNA lysis solution with 1% 2-ME. Total RNA was ex-
tracted using the GenEluteTM Total RNA Puriﬁcation kit
(Sigma-Aldrich) and treated with DNase I (Invitrogen).
Complementary DNA was synthesized from total RNA using
a reaction mix containing Tris-aminomethane (200mM), KCl
(500mM), MgCl2 (0.2M; Sigma-Aldrich), DTT (100mM;
Invitrogen), random hexamers (50 mM; Invitrogen), oligo(dT)
15 primer (100mg/ml; Promega), dNTP mix (10mM;
Promega), RNAsin (40 U/ml; Promega) and SuperScriptTM II
(200 U/ml; Invitrogen). After incubation at 42C for 50min
and inactivation at 99C for 3min, cDNA was diluted and
stored at 20C until use. For quantitative PCR, 0.2 mM for-
ward and reverse primer (Sigma-Aldrich), 10 mM probe
(Universal Probe Library; Roche Applied Science) and diluted
cDNA were added to TaqMan Universal PCR Master Mix.
Target gene expression was measured using optimal primer/
probe assays and TaqMan 7900HT (Applied Biosystems).
We used the following thermal cycle protocol: 2min at 50C
and 10min at 95C followed by 40 cycles of 15 s at 95C and
1min at 60C. CT values were analysed using SDS 2.4.1
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software (Applied Biosystems). Expression levels of target
genes were normalized using 18S rRNA as a reference.
Primer sequences are provided in Supplementary Table 2.
T cell transmigration assays
CD4+CD25/int memory T cells depleted from naı¨ve popula-
tions (CCR7+CD45RA+) were sorted by FACS and added at
2  105 cells/well to 3 mm pore size transwell plates (Corning).
Migration of Th17 subsets towards medium or CXCL10
(900 ng/ml; R&D Systems) was analysed after 3 h incubation
at 37C using FACS. To assess trans-endothelial migration of
Th17 subsets, migration experiments were performed across
conﬂuent monolayers of human brain endothelial cells
(hCMEC/D3 cell line) (Weksler et al., 2005) on collagen-
coated 5 mm pore size Transwell plate, as previously
described (Lopes Pinheiro et al., 2016). In this system,
5  105T helper memory cells were added per well and mi-
gration was assessed after 4 h.
Statistical analyses
Statistical analyses were carried out using Graphpad Prism
Software, version 5.04. We used the two-tailed Mann-
Whitney U-test to compare two independent groups and the
Wilcoxon matched-pairs signed rank test to compare samples
of the same persons. Correlations were tested using
Spearman’s rank. A logistic regression model was used to cor-
rect for MRI measurements in the multivariate analyses.
Experimental data are depicted as mean and standard error
of the mean. P-values50.05 were considered signiﬁcant.
Results
Low frequencies of Th1-like Th17 and
not Th17 effector cells in CIS blood
associate with rapid multiple sclerosis
onset
To search for pro-inﬂammatory T helper subsets that are
critically involved in early diagnosis of CDMS, we used per-
ipheral blood mononuclear cells at time of CIS from age-
and gender-matched patients who remained monophasic for
at least 5 years (CIS-CIS, n = 16) and from patients who
experienced a second attack within 1 year (CIS-CDMS,
n = 16; Table 1). Flow cytometric analysis of CD4+ T cells
showed decreased Th1-like Th17 (CCR6+CXCR3+) fre-
quencies in the CIS-CDMS group compared to the CIS-CIS
group (median: 5.9% versus 11.2%, P = 0.011; Fig. 1A).
After correction for lesion load on MRI at baseline, using
a logistic regression model, the association remains signiﬁ-
cant (OR: 0.78 per percent increase in Th1-like Th17;
P = 0.026). In CIS-CDMS, additional reductions in effector
memory (EM) to central memory (CM) ratios were found
for Th1-like Th17 (mean: 0.30 versus 0.50, P = 0.005;
Fig. 1B). Similar but less strong reductions were observed
for Th1 (CCR6CXCR3+; 10.0% versus 12.5%, P = 0.070
and mean EM/CM ratio: 0.21 versus 0.29, P = 0.021).
Frequencies and EM/CM ratios for Th17 (CCR6+
CXCR3) did not differ between CIS-CIS and CIS-CDMS
(Fig. 1A and B). T helper subset distribution in CIS patients
was not affected after stratiﬁcation for methylprednisolone
treatment in the last 3 months prior to sampling (data not
shown). Finally, Th1-like Th17 EM/CM ratios in CIS blood
inversely correlated to anti-EBNA1 IgG titres (P = 0.013;
Fig. 1C) and fatigue (P = 0.001; Fig. 1D), which were re-
ported as independent predictive markers for early CDMS
diagnosis (Lunemann et al., 2010; Runia et al., 2015).
Effector populations of highly
activated Th1-like Th17 cells are
reduced in blood after multiple
sclerosis diagnosis
To verify that these selective differences in T helper subsets
are associated with multiple sclerosis diagnosis, we
explored total frequencies of blood Th1 effector memory
and Th1-like Th17 effector memory cells in treatment-naive
RRMS patients (n = 18, Table 1), and age-/gender-matched
healthy controls (n = 19). Strongly reduced frequencies were
found for both these subsets in RRMS (median: 1.1% and
0.7%) compared to CIS-CIS (1.9%, P5 0.001 and 2.8%,
P5 0.0001, respectively) and healthy controls (2.8%,
P5 0.001 and 3.3%, P5 0.0001, respectively; Fig. 2A).
These frequencies did not signiﬁcantly differ between the
RRMS and CIS-CDMS (1.0% and 1.3%, respectively)
group. In RRMS, a signiﬁcant proportion of blood Th1-
like Th17 cells was positive for both CD38 and HLA-DR
(Fig. 2B), indicating a highly activated phenotype after mul-
tiple sclerosis diagnosis. This was not seen for Th1 cells
(Fig. 2B). These data suggest that Th1-like Th17 effector
cells are selectively activated in the periphery and recruited
to the CNS during multiple sclerosis onset.
Predominant expression of T-bet,
RORgt, IFN-g and GM-CSF, but not
IL-17A by activated blood Th1-like
Th17 cells
Human CCR6+ CD4+ T cells are not only strong producers
of IL-17, but also express IFN-g and GM-CSF (Cao et al.,
2015; Paulissen et al., 2015). To explore how these pro-in-
ﬂammatory cytokines are co-regulated in our phenotypically
deﬁned Th1-like Th17 (CCR6+CXCR3+) cells, T-bet and
RORgt, as well as IFN-g, GM-CSF and IL-17A expression
was compared to paired Th1 (CCR6CXCR3+) and Th17
(CCR6+CXCR3) populations from healthy blood donors.
Th1-like Th17 expressed both TBX21/T-bet and RORC/
RORgt mRNA at higher levels than Th1 (P = 0.016 and
P = 0.004) and Th17 (P = 0.008 and P = 0.039, respectively;
Fig. 3A). IFNG/IFN-g mRNA levels were similar between
Th1 and Th1-like Th17, while CSF2/GM-CSF mRNA
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levels in Th1-like Th17 were higher than in Th1
(P = 0.008) and Th17 (P = 0.020). Th1-like Th17 cells
only moderately expressed IL17A mRNA (Fig. 3B).
Differences in IFN-g, GM-CSF and IL-17A expression
were veriﬁed at the protein level (Fig. 3C). The percentage
of GM-CSF-positive cells was 2- to 3-fold higher in Th1-
like Th17 than in Th1 and Th17. IL-17A-positive cells
were 4-fold less present in Th1-like Th17 compared to
Th17. At the single-cell level, IFN-g was mainly co-ex-
pressed with GM-CSF and not with IL-17A in Th1-like
Th17 cells (Fig. 3D). These cytokine proﬁles were the
same for T helper subsets from CIS and RRMS blood
(data not shown). TNF expression was comparable be-
tween Th1, Th17 and Th1-like Th17 subsets (Fig. 3B).
CD226 was higher, while CD25 and FoxP3 were lower
expressed by Th1-like Th17 as compared to Th17 (Fig.
3A and Supplementary Table 3), which supported their
pro-inﬂammatory potential (Lozano et al., 2013; Gagliani
et al., 2015). Th1-like Th17 cells also showed sustained
CD161 expression (Supplementary Table 3), reﬂecting an
ex-Th17 phenotype (Annunziato et al., 2013).
Pro-inflammatory Th1-like Th17 cells
are abundant in CSF T cell cultures of
multiple sclerosis patients
To explore the local pro-inﬂammatory capacity of Th1-like
Th17 cells in early multiple sclerosis, CSF (n = 10) and
paired blood (n = 4) T cell subsets from early-stage multiple
sclerosis patients (Table 1) were analysed after short-term cul-
turing. Th1 and Th1-like Th17 were the main populations in
the CSF CD4+ T cell pool (Fig. 4A). Proportions of Th1-like
Th17 were higher than those of Th1 (P = 0.020) and their
equivalents in blood (2- to 3-fold increase; Fig. 4B). Similar
results were obtained with EM/CM ratios, which were high
for both subsets but most prominent in Th1-like Th17 cells in
CSF (Fig. 4C). Within the total CSF T cell pool, Th1-like Th17
cells were enriched and co-produced more IFN-g and GM-CSF
Figure 1 Reduction of Th1-like Th17 effector cells in the blood of CIS patients with short time to CDMS. CIS patients were
selected based on blood sampling within 4 months after diagnosis and time between CIS and CDMS. ‘CIS-CDMS’ patients were diagnosed with
CDMS within 1 year (n = 16; filled bars), while ‘CIS-CIS’ patients were not diagnosed with CDMS for at least 5 years (n = 16; shaded bars). CD4 +
T cells in the blood were compared for (A) Th1 (CCR6CXCR3 + ), Th17 (CCR6 + CXCR3) and Th1-like Th17 (CCR6 + CXCR3 + ) cell
distribution, as well as (B) effector memory (EM; CCR7CD45RA) to central memory (CM; CCR7 + CD45RA) cell ratios within each of these
subsets, as determined by flow cytometry. Th1-like Th17 effector to central memory cell ratios were correlated to reported predictors of early
CIS to CDMS transition, anti-EBNA1 IgG blood titre (C) and fatigue severity scale (FSS; D). *P5 0.05; **P5 0.01.
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compared to CCR6 and CCR6+ CD8+ T cells, and paired
blood counterparts (Fig. 4D–G). The percentage of IFN-g-posi-
tive cells was increased in CSF Th1-like Th17 versus Th1 (Fig.
4E). The enrichment of Th1-like Th17 in CSF compared to
blood (Fig. 4A and B) was also found in T cell cultures from
late-stage multiple sclerosis patients (n = 7, P = 0.016; Table 1
and Fig. 4H), suggesting that Th1-like Th17 recruitment to the
CNS also occurs at later stages of the disease.
Ex vivo Th1-like Th17 cells are
enriched in the CNS and accumulate
in the blood after natalizumab
treatment
To conﬁrm their recruitment to the CNS, we compared
ex vivo Th1 and Th1-like Th17 frequencies in single-cell
suspensions of 10 brain tissues and paired CSF and blood
samples of ﬁve patients with late-stage multiple sclerosis
(Table 1, Fig. 5A and B). Th1 and Th1-like Th17 cells
were over-represented, while Th17 cells were hardly seen
in multiple sclerosis brain tissues and CSF, in contrast to
blood. The enrichment of Th1-like Th17 was also found in
CSF, but was less in brain tissues from two non-demented
controls (Fig. 5B), suggesting that enhanced inﬁltration of
Th1-like Th17 cells into the brain parenchyma is associated
with multiple sclerosis (Kebir et al., 2009; Kunis et al.,
2013; Johnson et al., 2016).
In addition to chemokine receptors and pro-inﬂammatory
cytokines (Reboldi et al., 2009; Larochelle et al., 2011),
adhesion molecules play a key role in migration of periph-
eral T helper cells into the CNS, including VLA-4, MCAM
and PSGL-1 (Schneider-Hohendorf et al., 2014).
Interestingly, VLA-4, but not MCAM or PSGL-1, was the
most abundant on Th1-like Th17 cells (Supplementary
Table 3). In patients with RRMS (n = 14), blood Th1-like
Th17 proportions were elevated after 6 months of
treatment with natalizumab (anti-VLA-4 monoclonal anti-
body; median pre- versus post-treatment: 7.7% versus
10.4%, P = 0.006; Fig. 5C and Table 1). Th1-like Th17
cells did not show differences in EM/CM ratio (data not
shown), but their activation state (see also Fig. 2B) was
signiﬁcantly reduced after natalizumab therapy (Fig. 5D).
Th1-like Th17 showed increased capacity to produce IFN-g
and GM-CSF in post- versus pretreatment blood samples
(Fig. 5E and F). These results show that the effects of nata-
lizumab in multiple sclerosis are associated with an accu-
mulation of Th1-like Th17 cells in the blood.
Targeting of VLA-4high Th17.1 cells by
natalizumab in multiple sclerosis
patients who respond to treatment
To assess the selectivity of natalizumab effects on pro-inﬂam-
matory T helper populations in multiple sclerosis patients,
CCR4 was included as a surface marker in our ﬂow cyto-
metric panels for subdivision of Th1-like Th17 into recently
described pathogenic Th17.1 (IFN-ghighGM-CSFhighIL-17low)
and Th17 DP (IFN-glowGM-CSFlowIL-17int) subpopulations
(Ramesh et al., 2014; Paulissen et al., 2015). Th17.1
(CCR6+CXCR3+CCR4) frequencies were signiﬁcantly
increased in RRMS blood samples after both 6 and 12
months of treatment (median: 5.3% and 6.1%) versus pre-
treatment (3.7%; n = 14, both P = 0.0002; Table 1; Fig. 6A
and B). No signiﬁcant differences were found in Th1
(CCR6CXCR3+CCR4), Th17 (CCR6+CXCR3CCR4+)
and Th17 DP (CCR6+CXCR3+CCR4+) cells (Fig. 6A and
B). Importantly, this accumulation of Th17.1 was most pro-
nounced in natalizumab-treated patients who were free of
clinical relapses (n = 9; pretreatment, 3.8% versus 6
months post-treatment, 6.5% and 12 months post-treatment,
6.8%; P = 0.008 and P = 0.004, respectively). As compared
to patients who had relapses during treatment (n = 5;
Figure 2 Th1-like Th17 effector cells are highly activated and less present in the blood after multiple sclerosis diagnosis.
(A) Th1 and Th1-like Th17 effector memory (EM) frequencies in CD4 + T cells from CIS-CIS (n = 14) and CIS-CDMS (n = 16) as well as RRMS
(n = 18) and both age- and gender-matched healthy control (HC; n = 19) blood. (B) Highly activated fractions of blood Th1 and Th1-like Th17
cells in CIS-CIS (n = 14), CIS-CDMS (n = 16) and RRMS (n = 18) patients as well as HC (n = 19), as defined by co-expression of late T cell
activation markers HLA-DR and CD38. *P5 0.05; **P5 0.01; ***P5 0.001; ****P5 0.0001.
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pretreatment, 3.2% versus 6 months post-treatment, 4.0%
and 12 months post-treatment, 4.1%; Fig. 6C). The accu-
mulation of Th17.1 cells in the blood of clinical responders
was validated using a second cohort (Supplementary Table 1
and Supplementary Fig. 1A).
In pretreated RRMS blood, VLA-4 surface expression on
Th17.1 (mean MFI: 2603) was the highest of all pro-
inﬂammatory T helper subsets analysed, including Th1
(MFI: 1328, P = 0.001), Th17 (MFI: 1255, P = 0.0001)
and Th17 DP (MFI: 2038, P = 0.002; Fig. 6D and
Supplementary Fig. 1B). After natalizumab treatment,
VLA-4 was downregulated on all subsets analysed, but
this was most prominent for Th17.1 (mean reduction: 6
months post-treatment, 56%, 12 months post-treatment,
58%), as compared to Th1 (6 months post-treatment,
52%, P = 0.038; 12 months post-treatment, 54%,
P = 0.005), Th17 (6 months post-treatment, 37%,
P = 0.003; 12 months post-treatment, 38%, P = 0.0009)
and Th17 DP (6 months post-treatment, 49%, P = 0.002;
12 months post-treatment, 50%, P = 0.002; Fig. 6E). This
Figure 3 Blood Th1-like Th17 cells predominantly express T-bet and RORgt, and are high IFN-g and GM-CSF, but low IL-17A
producers. Buffy coats from nine healthy blood donors were used to assess gene expression of TBX21, RORC and FOXP3 (A), as well as IFNG,
CSF2, IL17A and TNF (B) in sorted Th1 (CCR6CXCR3 + ), Th17 (CCR6 + CXCR3) and Th1-like Th17 (CCR6 + CXCR3 + ) memory populations.
Cells were stimulated with PMA and ionomycin and mRNA levels were measured using quantitative PCR. (C) Flow cytometric analysis of
intracellular IFN-g, GM-CSF and IL-17A expression in PMA- and ionomycin-stimulated Th1, Th17 and Th1-like Th17 memory cells from the same
blood donors (n = 7). (D) Representative dot plots and quantification of co-expression of IFN-g with GM-CSF and IL-17A in Th1-like Th17
memory cells (n = 7). *P5 0.05; **P5 0.01.
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indicates that Th17.1 cells are preferentially targeted by
natalizumab treatment, preventing their transmigration
into the CNS of multiple sclerosis patients.
Pathogenic Th17.1 cells have a
superior capacity to transmigrate
into the CNS in early multiple
sclerosis
To study the CNS transmigration potential of Th17.1 in
multiple sclerosis further, we performed different in vitro
transwell migration assays using total T helper memory cell
fractions. Th17.1 was the main Th17 subpopulation
migrating across transwell ﬁlters towards inﬂammatory me-
diator CXCL10 (Sorensen et al., 2001) (Fig. 7A and B). No
migration was observed towards medium only (data not
shown). Particularly Th17.1 cells did show spontaneous
transmigration across human brain endothelial layers
(hCMEC/D3), which was enhanced under CXCL10-attract-
ing conditions (Fig. 7C and D).
In addition, ex vivo ﬂow cytometric analysis revealed an
enrichment of Th17.1 versus Th17 and Th17 DP cells in
CSF versus paired blood samples from four patients with
early-stage multiple sclerosis (three CIS and one RRMS;
Table 1, Fig. 7E and F). Consistently, lowered Th17.1 fre-
quencies were found in the blood from 26 CIS-CDMS
versus 21 CIS-CIS patients (P = 0.019), as well as 13
RRMS patients versus 12 matched healthy controls
(P = 0.031; Fig. 7G and Supplementary Table 1). Both
Th17.1 and Th17 DP cells were abundant in CSF com-
pared to blood from late-stage multiple sclerosis patients
(Supplementary Fig. 2).
Finally, to conﬁrm that Th17.1 is a distinct pro-inﬂam-
matory Th17 subset, we evaluated the expression of key
regulators of Th17 differentiation and pathogenicity.
Along with VLA-4 (see also Fig. 6D), CD161, CD226,
ABCB1 (MDR1), IL23R, STAT4, FCMR (TOSO) and
GZMB (granzyme B; all upregulated), as well as CD25
and BATF (downregulated) were discriminative markers
for Th17.1 (Supplementary Table 3 and Supplementary
Fig. 3). The abundant expression of T-bet, RORgt, IFN-g
and GM-CSF in Th17.1 cells (Supplementary Fig. 4) con-
ﬁrmed the pronounced Th1 features of this Th17 subset
(Paulissen et al., 2015).
Collectively, these data demonstrate the propensity of
Th17.1 cells to recruit to the CNS and mediate disease
activity in early multiple sclerosis.
Figure 4 Prevalence of pro-inflammatory Th1-like Th17 cells in CIS and multiple sclerosis CSF compared to blood T cell
cultures. (A–D) Presence of Th1-like Th17 (CCR6 + CXCR3 + ) subsets in short-term CSF T cell cultures from 10 early-stage multiple sclerosis
patients (CIS, n = 7; RRMS, n = 3). CSF Th1-like Th17 were compared to Th1 cells and their equivalents in blood for percentages in the total
CD4 + T cell pool (A and B) and for effector memory (EM) to central memory (CM) ratios (C) from the same patients. Similar analyses were
performed for CSF Th1-like Th17 and both CCR6 and CCR6 + CD8 + T cell subsets within the total T cell pool (D). These T cell subsets were
separated, stimulated with PMA and ionomycin and assessed for intracellular expression of (E) IFN-g, (F) GM-CSF and (G) IFN-g with GM-CSF.
For each analysis, Th1-like Th17 subsets were compared between paired CSF and blood T cell cultures. (H) Th1-like Th17 frequencies in T cell
cultures from paired blood and CSF of late-stage multiple sclerosis patients (n = 7). *P5 0.05; **P5 0.01.
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Figure 5 Th1-like Th17 recruitment to the CNS and targeting by natalizumab in multiple sclerosis patients. (A) Presence of Th1
(CCR6CXCR3 + ), Th17 (CCR6 + CXCR3) and Th1-like Th17 (CCR6 + CXCR3 + ) cells in single-cell suspensions from brain tissue, CSF and
blood of a patient with multiple sclerosis, as determined by FACS. (B) Th1-like Th17 frequencies in 10 brain tissues and paired CSF and blood
samples from five different multiple sclerosis patients (filled shapes). Similar analyses were performed for two non-demented control subjects
(NDC; open shapes). Each shape represents a different donor. For Th1-like Th17 cells in multiple sclerosis blood, frequencies (n = 14; C),
activation (n = 14; D) as well as pro-inflammatory capacities (n = 6; E and F) were determined before and 6 months after natalizumab treatment.
T cell activation was assessed by surface expression of both HLA-DR and CD38. To determine their pro-inflammatory capacity, Th1-like Th17
memory cells were isolated from pre- and post-treatment blood, stimulated with PMA and ionomycin, and stained for intracellular IFN-g and GM-
CSF. *P5 0.05; **P5 0.01.
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Figure 6 Selective accumulation of Th17.1 cells in natalizumab-treated multiple sclerosis patients who do not experience
clinical relapses. Using CCR4 as an additional marker, Th1-like Th17 cells were subdivided into Th17.1 (CCR6 + CXCR3 + CCR4) and Th17 DP
(CCR6 + CXCR3 + CCR4 + ) subsets and analysed in natalizumab-treated RRMS patients by flow cytometry (A). Th1 (CCR6CXCR3 + CCR4),
Th17 (CCR6 + CXCR3CCR4 + ), Th17.1 and Th17 DP cells were monitored in pre- and both 6 and 12 months post-treatment blood samples
(n = 14; B). Th17.1 proportions were separately evaluated in relapse-free (n = 9) and relapsing (n = 5) treatment groups (C). VLA-4 surface
expression levels were determined on these T helper subpopulations before (D) and both 6 and 12 months after (E) natalizumab treatment.
*P5 0.05; **P5 0.01; ***P5 0.001. MFI = mean fluorescent intensity; Tx = treatment.
1344 | BRAIN 2018: 141; 1334–1349 J. van Langelaar et al.
Downloaded from https://academic.oup.com/brain/article-abstract/141/5/1334/4961484
by Erasmus University Rotterdam user
on 22 June 2018
Discussion
In this study, we demonstrate that IFN-g- and GM-CSF-
expressing Th1-like Th17 (CCR6+CXCR3+) cells are
selectively associated with early disease activity in patients
with multiple sclerosis. During disease onset, highly acti-
vated and effector memory Th1-like Th17 cells are mark-
edly reduced in the peripheral blood and represents the
Figure 7 Enhanced CNS transmigration potential of Th17.1 cells and their recruitment to CSF in early multiple sclerosis. Total
T helper memory cells were sorted from healthy blood and used to assess the in vitro transmigration capacities of Th17, Th17.1 and Th17 DP cells
across transwell membranes (A and B; n = 6) and monolayers of human brain endothelial cells (BEC; C and D, n = 4) towards CXCL10. Each
experiment was performed in quintuplicate. Th17 subset distribution was assessed before (‘control’) and after migration towards medium or
CXCL10 using FACS. (E and F) Ex vivo Th17, Th17.1 and Th17 DP frequencies of CCR6 + T helper cells in paired CSF and blood from four early
multiple sclerosis patients. (G) The presence of Th17.1 cells in blood samples from 21 CIS-CIS, 26 CIS-CDMS and 13 treatment-naı¨ve RRMS
patients, as well as 12 healthy controls (HC), as determined by FACS. *P5 0.05.
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main pro-inﬂammatory T-cell population within CSF. This
local recruitment seemed to be preferentially targeted by
natalizumab treatment to prevent subsequent multiple scler-
osis relapses, since a Th1-like Th17 subpopulation termed
Th17.1, and no other T helper subsets, predominantly
accumulated in the blood of relapse-free patients. The cur-
rent work provides in-depth insights into the pro-inﬂamma-
tory capacity of distinct CCR6+ T helper subpopulations
during the course of multiple sclerosis (Cao et al., 2015),
and offers new possibilities to ﬁne-tune currently approved
T cell directed treatment for patients with multiple
sclerosis.
The use of both CCR6 and CXCR3 as discriminating
markers for Th17 cells does not only reﬂect their pro-in-
ﬂammatory state, but also their capability to migrate into
local inﬂammatory sites. Previous studies on Th17 cells in
experimental autoimmune encephalomyelitis and multiple
sclerosis primarily focused on single expression of CCR6
(Cao et al., 2015), or IL-17, which is increased in blood
and is further upregulated in CSF during a relapse
(Brucklacher-Waldert et al., 2009). Here, we demonstrated
that additional expression of CXCR3 subdivides human
CCR6+ Th17 into high (CXCR3) and low (CXCR3+)
producers of IL-17A. In these IL-17low producers, which
were over-represented in early-stage multiple sclerosis CSF
compared to blood T cell cultures, GM-CSF is the major
pro-inﬂammatory cytokine expressed together with IFN-g.
This is likely caused by their elevated levels of T-bet, and
not RORgt, as previously reported for human T helper cells
(Noster et al., 2014). The association of Th1-like Th17 (T-
bet-dependent) and not Th17 (RORgt-dependent) with a
short time to CDMS diagnosis is supported by the expres-
sion of T-bet, and not RORgt in CD4+ T cells during rapid
multiple sclerosis onset (Basdeo et al., 2016). Th1-like
Th17 cells were also highly activated after multiple sclerosis
diagnosis, which links to the important role of CD4+ T cell
activation in CIS progression (Corvol et al., 2008). This
suggests that during multiple sclerosis disease onset, the
loss of T regulatory function (Kleinewietfeld and Haﬂer,
2014) results in the activation of peripheral Th1-like
Th17 subsets, which inﬁltrate the CNS to mediate local
inﬂammation. Indeed, memory T helper cells of relapsing
multiple sclerosis patients were more capable of differen-
tiating into Th1-like Th17 cells, albeit co-producing IFN-g
and IL-17 (Kebir et al., 2009). These T helper cells were
cultured in the presence of IL-23, prompting RORgt and
subsequently IL-17 expression (Noster et al., 2014). In our
CCR6- and CXCR3-based approach, we deﬁned pro-in-
ﬂammatory cytokine proﬁles of Th17 and Th1-like Th17
populations directly from the blood. This could explain
why we identiﬁed IFN-g/GM-CSF- and not IL-17-produ-
cing Th17 cells as the most pro-inﬂammatory subset in
early multiple sclerosis, and also agrees with the minimal
inﬂuence of IL-17 and strong impact of GM-CSF on ex-
perimental autoimmune encephalomyelitis induction
(Ponomarev et al., 2007; Haak et al., 2009; Codarri
et al., 2011). For proper analysis of cytokine production
by Th1-like Th17 cells in CSF, we had to add IL-2 to short-
term T cell cultures, inducing GM-CSF expression (Noster
et al., 2014). Th1-like Th17 subsets co-produced more
IFN-g and GM-CSF than other T cell subsets in CSF and
their counterparts in blood. Our ﬁnding that pro-inﬂamma-
tory Th1-like Th17 and especially Th17.1 cells were highly
enriched in CSF of patients with early-stage multiple scler-
osis is in line with their reduced frequencies in the blood
(this study), and the increased CSF CD4 to CD14 ratios in
CIS patients with a short time to CDMS (Nemecek et al.,
2016). Consistent with in situ observations in multiple
sclerosis brain tissue (Kebir et al., 2009), a small fraction
of blood and CSF Th1-like Th17 and Th17.1 cells did co-
produce IFN-g and IL-17, but this was considerably less
than their co-production of IFN-g and GM-CSF. Besides
Th17.1, Th17 DP (IL-17int) cells were also enriched in
CSF of patients with late-stage multiple sclerosis, suggesting
that local IL-17 production is mainly involved in disease
progression. Nevertheless, the predominance of Th1-like
Th17 cells in multiple sclerosis CSF and brain tissues as
observed in this study corresponds to more recent ﬁndings
that CNS inﬂammation in multiple sclerosis is largely
mediated by inﬁltrating IFN-g- and not IL-17-producing
T helper cells (Kunis et al., 2013; Johnson et al., 2016;
Khaibullin et al., 2017).
Th1-like Th17 cells contain several features promoting
their selective intrusion into the CNS, although local
Th17 plasticity cannot be completely ruled out (Korn and
Kallies, 2017). Th1-like Th17 cells produce high levels of
IFN-g, triggering CXCL10 expression by endothelial cells
to favour CXCR3-mediated migration into the CNS (Kunis
et al., 2013; Paroni et al., 2017), and thereby multiple
sclerosis disease activity (Mahad et al., 2002), which is
supported by our in vitro and ex vivo transmigration re-
sults. Additional expression of GM-CSF by this subset may
further dysregulate the blood–brain barrier, as described
for monocytes (Vogel et al., 2015). Prior to their extrava-
sation, Th17 cells make use of distinct molecules involved
in the rolling on and adhesion to endothelial cells, which
are activated by pro-inﬂammatory cytokines and chemo-
kines (Engelhardt and Ransohoff, 2012; Larochelle et al.,
2012; Schneider-Hohendorf et al., 2014). One of these mol-
ecules is the a4b1-integrin VLA-4, which is targeted by
natalizumab to cause a strong reduction of lymphocytes
in multiple sclerosis CSF (Stuve et al., 2006). In addition
to previous work (Kivisakk et al., 2009), we now show
that only a particular Th1-like Th17 subpopulation
termed Th17.1 accumulates in the blood from multiple
sclerosis patients who clinically respond to natalizumab
treatment. These selective effects may thus be useful for
predicting freedom from multiple sclerosis activity
(Prosperini et al., 2012), and understanding the potential
lethal multiple sclerosis rebounds that occur in patients
who have to stop this treatment due to increased risk of
progressive multifocal leukoencephalopathy (PML)
(Sorensen et al., 2014; Larochelle et al., 2017). Multiple
sclerosis rebounds are characterized by a rapid inﬂux of
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pro-inﬂammatory cells into the CNS to cause excessive in-
ﬂammation, potentially resulting in PML-immune reconsti-
tution inﬂammatory syndrome (IRIS) (Tan et al., 2011).
Although not proven yet, the marked accumulation of
Th17.1 in natalizumab-treated multiple sclerosis blood puts
forward their transmigration into the CNS as a critical pro-
cess during these complications. Out of all pro-inﬂammatory
T helper subsets deﬁned by CCR6, CXCR3 and CCR4,
Th17.1 revealed the strongest VLA-4 surface expression
levels in multiple sclerosis blood, which explains their
restricted targeting by natalizumab. Consistent with our re-
sults, VLA-4 levels were found to be higher on Th17 than
on Th1 cells in multiple sclerosis patients, probably mediat-
ing their trafﬁcking into the CNS (Brucklacher-Waldert
et al., 2009). However, when we compared individual
Th17 subpopulations, i.e. CCR6+ Th17 (CXCR3CCR4+;
IL-17high), Th17 DP (CXCR3+CCR4+; IL-17dim) and
Th17.1 (CXCR3+CCR4; IL-17low) (Paulissen et al.,
2015), VLA-4 surface expression seemed to be inversely
associated with their ability to produce IL-17, as also
described for mice (Rothhammer et al., 2011). The predom-
inant expression of VLA-4 on Th17.1 cells closely parallels
the dependence of IFN-g- and not IL-17-producing T helper
cells on this integrin for their entry into the CNS during
experimental autoimmune encephalomyelitis (Baron et al.,
1993; Rothhammer et al., 2011). However, adhesion mol-
ecules other than VLA-4 must be taken into account for
alternative transmigration routes of pro-inﬂammatory Th17
cells as well (Engelhardt and Ransohoff, 2012), especially
considering the rebound effects after natalizumab discontinu-
ation in multiple sclerosis.
This cross-sectional study exempliﬁes that a more reﬁned
evaluation of chemokine surface receptors, pro-inﬂammatory
cytokines and adhesion molecules is warranted to better
understand the contribution of human Th1 and Th17 to
multiple sclerosis and other autoimmune and neuroinﬂam-
matory diseases. Based on CCR6/CXCR3, IFN-g/GM-CSF
and VLA-4 expression, we identify Th1-like Th17 as a clin-
ically relevant CD4+ T cell population during disease onset
and treatment in multiple sclerosis patients. Future work on
the localization and antigen speciﬁcity of these subsets in
human brain lesions will be critical to determine their
local impact on myelin and axonal loss in multiple
sclerosis. The prominent association of Th1-like Th17
cells, in particular Th17.1, with multiple sclerosis activity
suggests the possibility for more speciﬁc T cell-targeted
therapies, and pleads for further assessment of the use of
natalizumab earlier in the disease course of multiple sclerosis
(Nicholas et al., 2014).
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